Skip to main content
SpringerLink
Log in

Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3

  • Original articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Ganglioside GD3, which is one of the major gangliosides expressed on the cell surface human tumors of neuroectodermal origin, has been studied as a target molecule for passive immunotherapy. We established ten kinds of anti-GD3 monoclonal antibodies (mAb) of the mouse IgG3 subclass by immunization with purified GD3 and melanoma cells. One of the established mAb, KM641, showed major reactivity with GD3 and minor reactivity with GQ1b out of 11 common gangliosides in an enzymelinked immunosorbent assay. Immunostaining of gangliosides, separated on thin-layer chromatography plates, using KM641 revealed that most of the melanoma cell lines contained immunoreactive GD3 and GD3-lactone at a high level, but only the adrenal gland and the urinary bladder out of 21 human normal tissues had immunoreactive GD3. In immunofluorescence, KM641 bound to a variety of living tumor cell lines especially melanoma cells, including some cell lines to which another anti-GD3 mAb R24, established previously, failed to bind. High-affinity binding of KM641 to a tumor cell line was quantified by Scatchard analysis (K d = 1.9×10−8 M). KM641 exerted tumor-killing activity in the presence of effector cells or complement against melanoma cells expressing GD3 at a high level. Not only natural killer cells but also polymorphonuclear cells were effective as the effector cells in antibody-dependent cellular cytotoxicity. Intravenous injection of KM641 markedly suppressed the tumor growth of a slightly positive cell line, C24.22 (7.2×105 binding sites/cell), as well as a very GD3-positive cell line, G361 (1.9×107 binding sites/cell), inoculated intradermally in nude mice. KM641, characterized by a high binding affinity for GD3, has the potential to be a useful agent for passive immunotherapy of human cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Baker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA (1991) Effects of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 51: 144

    Google Scholar 

  2. Bernhard H, Bauerschmitz J, Büschenfelde K-H, Dippold W (1992) Immunorecognition of different ganglioside epitopes on human normal and melanoma tissues. Int J Cancer 51: 568

    Google Scholar 

  3. Chapman PB, Yuasa H, Houghton A (1990) Homophilic binding of mouse monoclonal antibodies. J Immunol 145: 891

    Google Scholar 

  4. Chapman PB, Lonberg M, Houghton AN (1990) Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship between avidity, effector functions, tumor targeting, and anti-tumor activity. Cancer Res 50: 1503

    Google Scholar 

  5. Cheresh DA, Harper JR, Schulz G, Reisfeld RA (1984) Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci USA 81: 5767

    Google Scholar 

  6. Cheung NV, Lazarus H, Miraldi FD (1987) Ganglioside GD2 specific monoclonal antibody 3F8: a phase-I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5: 1430

    Google Scholar 

  7. Dippold W, Lloyd KO, Li LTC, Ikeda H, Oettgen HF, Old LJ (1980) Cell-surface antigens of human malignant melanoma-definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci USA 77: 6114

    Google Scholar 

  8. Garin-Chesa P, Bevesford HR, Carrato-Mena A, Oettgen HF, Old LJ, Melamed MR, Rettig WJ (1989) Cell surface molecules of human melanoma: immunohistochemical analysis of the gp57, GD3, and mel-CSPG antigen systems. Am J Pathol 134: 295–303

    Google Scholar 

  9. Hakomori S (1985) Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res 45: 2405

    Google Scholar 

  10. Hanai N, Shitara K, Yoshida H (1986) Generation of monoclonal antibodies against human lung squamous cell carcinoma and adenocarcinoma using mice rendered tolerant to normal human lung. Cancer Res 46: 4438

    Google Scholar 

  11. Hanai N, Nores GA, MacLeod C, Torres-Mendez C-R, Hakomori S (1988) Ganglioside-mediated modulation of cell growth. J Biol Chem 263: 10915

    Google Scholar 

  12. Hanai N, Furuya A, Shitara K, Oda S, Yoshida H (1988) Comparative studies on monoclonal antibodies raised against human gastric cancer for application to serum diagnosis of cancer. Anticancer Res 8: 329

    Google Scholar 

  13. Hanai N, Shitara K, Furuya A, Yoshida H, Dohi T, Nudelman E, Hakomori S, Satoh S (1990) Detailed characterization of reactivities of anti-gastric cancer monoclonal antibodies to carbohydrate antigen. Anticancer Res 10: 1579

    Google Scholar 

  14. He X, Wikstrand CJ, Fredman P, Månsson J-E, Svennerholm L, Bigner DD (1989) GD3 expression by cultured human tumor cells of neuroectodermal origin. Acta Neuropathol 79: 317

    Google Scholar 

  15. Hellström I, Brankovan V, Hellström KE (1985) Strong anti-tumor activities of IgG3 antibodies to a human melanoma-associated ganglioside. Proc Natl Acad Sci USA 82: 1499

    Google Scholar 

  16. Holm M, Mansson J-E, Vanier M-T, Svennerholm L (1972) Gangliosides of human, bovine and rabbit retina. Biochim Biophys Acta 280: 356

    Google Scholar 

  17. Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadham S, Carswell E, Melamed MR, Oettgen H, Old LJ (1985) Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase-I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82: 1242

    Google Scholar 

  18. Irie RF, Morton DL (1986) Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside. Proc Natl Acad Sci USA 83: 8694

    Google Scholar 

  19. Irie RF, Matsuki T, Morton DL (1989) Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet 4: 786

    Google Scholar 

  20. Jennemann R, Rodden A, Bauer BL, Mennel H-D, Wiegandt H (1990) Glycosphinogolipids of human gliomas. Cancer Res 50: 7444

    Google Scholar 

  21. Junghans RP, Waldmann TA, Landolfi NF, Avdalovic NM, Schneider WP, Queen C (1990) Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res 50: 1495

    Google Scholar 

  22. Kawashima I, Tada N, Fujimori T, Tai T (1990) Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro. J Biochem (Tokyo) 108: 109

    Google Scholar 

  23. Llipoulos D, Ernst C, Steplewski Z, Jambarosic JA, Rodeck U, Herlyn M, Clark WH, Koprowski H, Herlyn D (1989) Inhibition of metastasis of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides. JNCI 81: 440

    Google Scholar 

  24. Mujoo K, Reisfeld RA, Cheung L, Rosenblum MG (1991) A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2. Cancer Immunol Immunother 34: 198

    Google Scholar 

  25. Nudelman E, Hakomori S, Kannagi R, Levery S, Yeh M-Y, Hellström KE, Hellström I (1982) Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2. J Biol Chem 257: 12752

    Google Scholar 

  26. Portoukalian J, Zwingelstein G, Dore J (1979) Lipid composition of human malignant melanoma tumors of various levels of malignant growth. Eur J Biochem 94: 19

    Google Scholar 

  27. Pukel CS, Lloyd KO, Travassor R, Dippold WG, Oettgen HF, Old LJ (1982) GD3, a prominent ganglioside of human melanoma. J Exp Med 115: 1133

    Google Scholar 

  28. Ravindranath MH, Tsuchida T, Morton DL, Irie RI (1991) Ganglioside GM3: GD3 ratio as an index for the management of melanoma. Cancer 67: 3029

    Google Scholar 

  29. Real FX, Houghton AN, Albino AP, Cordon-Cardo C, Melamed MR, Oettgen HF, Old LJ (1985) Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: Specificity analysis and comparison of expression in cultured cells and tissues. Cancer Res 45: 4401

    Google Scholar 

  30. Shitara K, Hanai N, Kusano A, Furuya A, Yoshida H, Wada K, Watanabe T, Sato S (1991) Application of anti-sialyl Lea monoclonal antibody, KM231, for immunotherapy of cancer. Anticancer Res 11: 2003

    Google Scholar 

  31. Svennerholm L (1963) Chromatographic separation of human brain gangliosides. J Neurochem 10: 613

    Google Scholar 

  32. Tai T, Kawashima I, Furukawa K, Lloyd KO (1988) Monoclonal antibody R24 distinguishes between differentN-acetyl-andN-glycolyl neurominic acid derivatives of ganglioside GD3. Arch Biochem Biophys 260: 51

    Google Scholar 

  33. Tsuchida T, Ravindranath MH, Saxton RE, Irie RF (1987) Gangliosides of human melanoma: altered expression in vivo and in vitro. Cancer Res 47: 1278

    Google Scholar 

  34. Tsuchida T, Saxton RE, Morton DL, Irie RF (1987) Gangliosides of human melanoma. JNCI 78: 45

    Google Scholar 

  35. Vadhan-Raj S, Cordon-Cardo C, Carswell E, Mintzer D, Dantis L, Duteau C, Templeton MA, Oettgen HF, Old LJ, Houghton AN (1988) Phase-I trial of a mouse monoclonal against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol 6: 1636

    Google Scholar 

  36. Watarai S, Onuma M, Yasuda T (1991) Production of monoclonal antibodies specific for gangliosides GD3. J Biochem (Tokyo) 110: 889

    Google Scholar 

  37. Werkmeister JA, Triglia T, Mackay IR, Dowling JP, Varigos GA, Morstyn G, Burns GF (1987) Fluctuations in the expression of a glycolipid antigen associated with differentiation of melanoma cells monitored by a monoclonal antibody, Leo Mel 3. Cancer Res 47: 225

    Google Scholar 

  38. Winter G, Milstein C (1991) Man-made antibodies. Nature 349: 293

    Google Scholar 

  39. Yates AJ, Thompson PK, Boesel CP, Albrightson C, Hart RW (1979) Lipid composition of human neural tumors. J Lipid Res 20: 428

    Google Scholar 

  40. Yeh MY, Hellström I, Abe K, Hakomori S, Hellström KE (1982) Cell-surface antigen which is present in the ganglioside fraction and shared by human melanomas. Int J Cancer 29: 269

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Immunology, Tokyo Research Laboratories, Kyowa Hakko Kogyo Co. Ltd., 3-6-6 Asahi-machi, 194, Machida, Tokyo, Japan

    So Ohta, Ayumi Honda, Yuko Tokutake, Hajime Yoshida & Nobuo Hanai

Authors
  1. So Ohta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ayumi Honda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuko Tokutake
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hajime Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nobuo Hanai
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ohta, S., Honda, A., Tokutake, Y. et al. Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3. Cancer Immunol Immunother 36, 260–266 (1993). https://doi.org/10.1007/BF01740908

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01740908

Key words

Search

Navigation